- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02568332
A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals
A Phase I Study to Assess the Safety and Immunogenicity of Prime-boost Immunisations With Vaccine Candidates AdCh3NSmut1 and MVA-NSmut in HIV-1 Seropositive HCV-uninfected Adults on Antiretroviral Therapy (ART)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hepatitis C (Hep C) is a common infection. Worldwide, over 180 million people are infected. Hep C is a blood borne viral infection spread through direct contact with the blood of an infected person. People with Hep C frequently have no symptoms and infection can lead to fibrosis (scarring of the liver), liver failure and cancer. Infection with the Hep C virus (HCV) progresses more rapidly to liver damage in Human Immunodeficiency Virus (HIV)-infected individuals.
Researchers at the University of Oxford have developed a novel candidate vaccine against HCV ('NSmut'). This vaccine has been inserted into the carrier viruses Chimpanzee Adenovirus 3 (AdCh3) and modified vaccinia virus Ankara (MVA), both of which have excellent safety records and have been previously tested in people.
However, the objective of this study is to use exploratory immunological assays to assess whether vaccines for Hep C can induce immune responses in HIV positive individuals that are similar in strength to those in healthy volunteers.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Dublin, Ireland, Dublin 8
- St James's Hospital
-
-
-
-
-
St. Gallen, Switzerland, 9007
- Kantonsspital St. Gallen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
HIV-1 seropositive adults must satisfy all the following inclusion criteria to be eligible for the study:
- Aged 18 to 60 years (inclusive)
- Resident in or near the trial sites for the duration of the vaccination study for the participant
- Able and willing (in the Investigator's opinion) to comply with all study requirements
- HIV Viral Load <50 copies/mL at the last routine HIV follow-up visit within the last 9 months prior to inclusion whilst on treatment with an effective ART regimen
- Willingness to remain on ART for the study duration
- CD4 cell count above 350 cells/uL
- Negative HCV serology and negative HCV RNA polymerase chain reaction (PCR) testing
For women of child bearing potential, willingness to practise continuous effective contraception during the study and a negative pregnancy test on the day(s) of vaccination. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and, when applicable, in accordance with the product label. In subjects on ART, these are:
- Injectable progestogen
- Male partner sterilisation prior to the female subject's entry into the study, and this male is the sole partner for that subject
- Male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository)
- Intrauterine device or intrauterine system
- In addition male partners should use condoms until 3 months after the last vaccination
Male trial participants with a female partner of child bearing potential should use condoms until 3 months after the last vaccination. In addition, the female partner should use one of the following contraceptive methods, i.e.
- Oral or injectable hormonal contraception
- Sterilisation
- Intrauterine device or intrauterine system
- Male trial participants with pregnant partners should use condoms until 3 months after the last vaccination
- Written informed consent
Exclusion Criteria:
HIV-1 seropositive adults may not enter the study if any of the following exclusion criteria apply:
- Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
- Prior receipt of a recombinant simian or human adenoviral vaccine
- Clinical, biochemical (abnormal liver synthetic dysfunction defined by an elevated blood prothrombin time or a low blood albumin level), ultrasonographic, FibroscanTM, or liver biopsy (histology) evidence of cirrhosis or portal hypertension
- Ongoing or recent (<12 months) AIDS defining illness (US Centers for Disease Control and Prevention (CDC) definition)
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, including egg products or gentamicin.
- History of clinically significant contact dermatitis
- Any history of anaphylaxis or serious reaction in relation to vaccination
- Pregnancy, lactation or willingness/intention to become pregnant during the study
- Known active malignant disease (except basal cell carcinoma of the skin and cervical carcinoma in situ)
- Current suspected or known injecting drug abuse (except individuals participating in a heroin substitution program without known or suspected concomitant drug abuse). Participants will be counselled regarding the risk of HCV acquisition during the trial.
- Seropositive for hepatitis B surface antigen (HBsAg)
- Positive test for Hepatitis C antibody and/or PCR
- Moderate neutropenia (Absolute neutrophil count of <1,000 cells/uL)
- Moderate thrombocytopenia (Platelet count <80,000 cells/uL)
- Anaemia (Haemoglobin <10g/dL)
- History of pericarditis and/or myocarditis
- Heart failure (left ventricular ejection fraction <20%) in the patient history or current medical treatment for heart failure.
- History of immunologically mediated disease (e.g. inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis requiring more than intermittent nonsteroidal anti-inflammatory medications for management)
- History of organ transplantation
- History of severe psychiatric disease, including psychosis and/or depression, characterised by a suicide attempt, hospitalisation for psychiatric disease, or a period of disability as a result of psychiatric disease.
- History of a significant coagulopathy (i.e. International Normalised Ratio (INR) > 1.3 and/or Activated Partial Thromboplastin Time (APTT) > 1.5 upper limits of normal) or anticoagulant therapy at time of vaccination
- Receipt of any oral or systemic antineoplastic or immunomodulatory (e.g. oral systemic corticosteroids) treatment or radiation within 24 weeks before Day 0 or the expectation that such treatment will be needed at any time during the study. Topical or inhaled corticosteroid use is allowed.
- Any other significant disease, disorder or finding, which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or may influence the result of the study, or the patient's ability to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8. Subjects: 20 HIV seropositive individuals |
Genetic vaccine against Hepatitis C virus infection
Genetic vaccine against Hepatitis C virus infection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of administering HCV prime-boost vaccinations to HIV seropositive individuals, as measured by the proportion of participants who develop a grade 3 or 4 local or systemic reaction
Time Frame: From Day 0 until 6 months after the last vaccination
|
From Day 0 until 6 months after the last vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cellular immune response generated by HCV prime-boost vaccinations in HIV seropositive individuals, as determined by analysing changes in the magnitude or quality of HCV-specific cellular immune responses
Time Frame: From Day 0 until 6 months after the last vaccination
|
Immunogenicity determined by analysing changes from baseline in the magnitude or quality of HCV-specific cellular immune responses.
The primary outcome measure for immunogenicity will be the development of T cell responses to HCV epitopes, as determined by Interferon (IFN)-ɣ Enzyme-Linked ImmunoSpot (ELISpot) assay.
|
From Day 0 until 6 months after the last vaccination
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Lucy Dorrell, Prof, University of Oxford
- Principal Investigator: Ellie Barnes, Prof, University of Oxford
- Principal Investigator: Matthias Hoffmann, Dr, Cantonal Hospital of St. Gallen
- Principal Investigator: Colm Bergin, Prof, St. James's Hospital, Dublin
- Principal Investigator: Pietro Vernazza, Prof, Cantonal Hospital of St. Gallen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEACHI-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C Infection
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
University Health Network, TorontoCompletedChronic Hepatitis C Virus InfectionCanada
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical UniversityRecruitingChronic Hepatitis C InfectionChina
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
PharmaEssentiaCompletedChronic Hepatitis C Virus InfectionKorea, Republic of, Taiwan, China
-
Gilead SciencesCompleted
-
Gilead SciencesCompletedChronic Hepatitis C InfectionNew Zealand
-
Humanity and Health Research CentreEmory University; Beijing 302 HospitalCompleted
Clinical Trials on AdCh3NSmut1
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of OxfordGlaxoSmithKline; ReiThera SrlCompletedHIV Infection | Hepatitis C InfectionUnited Kingdom
-
ReiThera SrlUniversity of Oxford; Oxford University Hospitals NHS Trust; University Hospital...Completed